Drug Profile
MVA-BN-PRO
Alternative Names: MVA-BN-PROLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator BN ImmunoTherapeutics
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 18 Feb 2013 Interim adverse events and immunogenicity data from a phase I/II trial in Prostate cancer (hormone-refractory, non-metastatic) released by Bavarian Nordic
- 01 Sep 2011 BN ImmunoTherapeutics completes a phase I trial in Prostate cancer (hormone-refractory, non-metastatic) in USA (NCT00629057)
- 04 Jun 2008 Phase-I/II clinical trials in Prostate cancer (hormone-refractory, non-metastatic) in USA (SC)